Comparison of Bimatoprost and Timolol for Treatment of Chronic Angle Closure Glaucoma
Bimatoprost Versus Timolol in Chronic Glaucoma
DOI:
https://doi.org/10.54393/pjhs.v5i07.1354Keywords:
Bimatoprost, Conjunctival Hyperaemia, Intraocular Pressure, Pruritius, Timolol, GlaucomaAbstract
Angle-closure glaucoma occurs when the normal drainage of fluid within the eye, specifically the aqueous humor, is obstructed or restricted. Objective: To assess and compare bimatoprost 0.03% administered once daily versus timolol 0.5% administered twice daily in patients diagnosed with chronic angle closure glaucoma (CACG). Methods: This randomized controlled study was performed at the Department of Ophthalmology, Bahawalpur Victoria Hospital, Bahawalpur, Pakistan, from August 2023 to January 2024. Patients of either gender, aged 18 years or older, and diagnosed with unilateral or bilateral CACG were included. Patients were randomly allocated to either Bimatoprost 0.03% (once daily at night) or Timolol malete 0.5% (two times morning and night daily) adopting a lottery method. Patients were asked to visit after one and 3 months (final outcome) and intraocular pressure (IOP) measurements were taken between 8 to 10 am using an applanation tonometer. Results: A total of 110 patients of which 64 (58.2%) were female. The mean age was 58.9 ± 10.5 years. At baseline, the mean intraocular pressure was calculated to be 24.2 ± 5.7 mmHg. After 1-month (18.7 ± 4.2 mmHg vs. 20.5 ± 4.7 mmHg, p=0.0418) and 3-months of treatment (16.8±4.6 mmHg vs. 19.6 ± 4.3 mmHg, p=0.0030), the mean IOP were significantly less in Bimatoprost group when compared to Timolol group. The commonest adverse events were conjunctival hyperaemia, and pruritus reported by 19 (17.3%), and 9 (8.2%) patients respectively. Conclusions: Bimatoprost exhibited a significantly better reduction in IOP compared to timolol in chronic angle closure glaucoma. Both drugs showed relatively good safety and tolerability profiles.
References
Zhang N, Wang J, Chen B, Li Y, Jiang B. Prevalence of primary angle closure glaucoma in the last 20 years: a meta-analysis and systematic review. Frontiers in Medicine. 2021 Jan; 18(7): 624179. doi: 10.3389/fmed.2020.624179. DOI: https://doi.org/10.3389/fmed.2020.624179
Hashemi H, Mohammadi M, Zandvakil N, Khabazkhoob M, Emamian MH, Shariati M et al. Prevalence and risk factors of glaucoma in an adult population from Shahroud, Iran. Journal of Current Ophthalmology. 2019 Dec; 31(4): 366-72. doi: 10.1016/j.joco.2018.05.003. DOI: https://doi.org/10.1016/j.joco.2018.05.003
Shiose Y. Epidemiology of glaucoma in Japan. A nationwide glausoma survey. Japanese Journal of Ophthalmology. 1991; 35: 13-5.
Park SJ, Park KH, Kim TW, Park BJ. Nationwide incidence of acute angle closure glaucoma in Korea from 2011 to 2015. Journal of Korean Medical Science. 2019 Dec; 34(48). doi: 10.3346/jkms.2019.34.e306. DOI: https://doi.org/10.3346/jkms.2019.34.e306
Schuster AK, Erb C, Hoffmann EM, Dietlein T, Pfeiffer N. The diagnosis and treatment of glaucoma. Deutsches Ärzteblatt International. 2020 Mar; 117(13): 225. doi: 10.3238/arztebl.2020.0225. DOI: https://doi.org/10.3238/arztebl.2020.0225
Wagner IV, Stewart MW, Dorairaj SK. Updates on the Diagnosis and Management of Glaucoma. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2022 Dec; 6(6): 618-35. doi: 10.1016/j.mayocpiqo.2022.09.007. DOI: https://doi.org/10.1016/j.mayocpiqo.2022.09.007
Nüßle S, Reinhard T, Lübke J. Acute closed-angle glaucoma—an ophthalmological emergency. Deutsches Ärzteblatt International. 2021 Nov; 118(45): 771. doi: 10.3238/arztebl.m2021.0264. DOI: https://doi.org/10.3238/arztebl.m2021.0264
Yen CY, Chen CC, Tseng PC. Role of pilocarpine use following laser peripheral iridotomy in eyes with refractory acute angle closure glaucoma: A case report and literature review. Medicine. 2022 Jul; 101(27): e29245. doi: 10.1097/MD.0000000000029245. DOI: https://doi.org/10.1097/MD.0000000000029245
Krishnadas R. Current management options in primary angle closure disease. Indian Journal of Ophthalmology. 2019 Mar; 67(3): 321-3. doi: 10.4103/ijo.IJO_1932_18. DOI: https://doi.org/10.4103/ijo.IJO_1932_18
Wanichwecharungruang B, Phumratprapin C, Kongsomboon K, Seresirikachorn K. Real-world surgical outcomes of primary angle-closure glaucoma. Clinical Ophthalmology. 2021 Jun; 2823-33. doi: 10.2147/OPTH.S315747. DOI: https://doi.org/10.2147/OPTH.S315747
Feng H, Han D, Lu W, Tang G, Zhang H, Fan S et al. Efficacy of Morning Versus Evening Latanoprost/Timolol Fixed Combination for Open-Angle Glaucoma and Ocular Hypertension: A Randomized Clinical Trial. Translational Vision Science & Technology. 2024 Jan; 13(1): 21-. doi: 10.1167/tvst.13.1.21. DOI: https://doi.org/10.1167/tvst.13.1.21
Zhou L, Zhan W, Wei X. Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Frontiers in Pharmacology. 2022 Oct; 13: 1015338. doi: 10.3389/fphar.2022.1015338. DOI: https://doi.org/10.3389/fphar.2022.1015338
Qing G, Wang N, Mu D. Efficacy of goniosynechialysis for advanced chronic angle-closure glaucoma. Clinical ophthalmology. 2012 Oct; 1723-9. doi: 10.2147/OPTH.S34035. DOI: https://doi.org/10.2147/OPTH.S34035
Rojanapongpun P, Tantisevi V. Medical Therapy in Angle Closure Glaucoma. Primary Angle Closure Glaucoma (PACG) A Logical Approach in Management. 2021: 31-44. doi: 10.1007/978-981-15-8120-5_4. DOI: https://doi.org/10.1007/978-981-15-8120-5_4
Chen YY, Wang TH, Liu C, Wu KY, Chiu SL, Simonyi S et al. Tolerability and efficacy of bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01%(APPEAL Taiwan) study. BioMed Central Ophthalmology. 2016 Dec; 16: 1-8. doi: 10.1186/s12886-016-0338-6. DOI: https://doi.org/10.1186/s12886-016-0338-6
García-López A, Paczka JA, Jiménez-Román J, Hartleben C. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. BioMed Central Ophthalmology. 2014 Dec; 14: 1-2. doi: 10.1186/1471-2415-14-161. DOI: https://doi.org/10.1186/1471-2415-14-161
Agarwal HC, Gupta V, Sihota R. Effect of changing from concomitant timolol pilocarpine to bimatoprost monotherapy on ocular blood flow and IOP in primary chronic angle closure glaucoma. Journal of ocular pharmacology and therapeutics. 2003 Apr; 19(2): 105-12. doi: 10.1089/108076803321637636. DOI: https://doi.org/10.1089/108076803321637636
Chew PT, Aung T, Aquino MV, Rojanapongpun P, EXACT Study Group. Intraocular pressure–reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. Ophthalmology. 2004 Mar; 111(3): 427-34. doi: 10.1016/j.ophtha.2003.06.007. DOI: https://doi.org/10.1016/j.ophtha.2003.06.007
Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Archives of Ophthalmology. 2002 Oct; 120(10): 1286-93. doi: 10.1001/archopht.120.10.1286. DOI: https://doi.org/10.1001/archopht.120.10.1286
Chen HY, Huang WC, Lin CL, Kao CH. Association between topical beta-blockers and risks of cardiovascular and respiratory disease in patients with glaucoma: a retrospective cohort study. British Medical Journal Open. 2020 Jul; 10(7): e034361. doi: 10.1136/bmjopen-2019-034361. DOI: https://doi.org/10.1136/bmjopen-2019-034361
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
